LCT.AX
Living Cell Technologies Ltd
Price:  
0.01 
AUD
Volume:  
1,378,040
Australia | Biotechnology

LCT.AX WACC - Weighted Average Cost of Capital

The WACC of Living Cell Technologies Ltd (LCT.AX) is 6.1%.

The Cost of Equity of Living Cell Technologies Ltd (LCT.AX) is 8.1%.
The Cost of Debt of Living Cell Technologies Ltd (LCT.AX) is 5%.

RangeSelected
Cost of equity5.3% - 10.9%8.1%
Tax rate14.0% - 18.7%16.35%
Cost of debt5.0% - 5.0%5%
WACC4.8% - 7.5%6.1%
WACC

LCT.AX WACC calculation

CategoryLowHigh
Long-term bond rate4.1%4.6%
Equity market risk premium5.5%6.5%
Adjusted beta-0.060.65
Additional risk adjustments1.5%2.0%
Cost of equity5.3%10.9%
Tax rate14.0%18.7%
Debt/Equity ratio
11
Cost of debt5.0%5.0%
After-tax WACC4.8%7.5%
Selected WACC6.1%

LCT.AX's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for LCT.AX:

cost_of_equity (8.10%) = risk_free_rate (4.35%) + equity_risk_premium (6.00%) * adjusted_beta (-0.06) + risk_adjustments (1.75%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.